Hikma Pharmaceuticals Egypt launches Hikma Specialized division to bring advanced affordable medicines to patients in need

Cairo, June, 2016 - Hikma Pharmaceuticals Egypt announced early this month, the launch of its new business unit 'Hikma Specialized Egypt' as part of their strategic vision focusing on high need areas and providing access to affordable high tech therapies to patients. The creation of Hikma Specialized is seen as a strategic move to improve the company's ability to meet the unique and urgent needs of cancer patients and health care providers in Egypt.

'Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease,' said Tareq Darwazah, Hikma Specialized Business Unit Director. 'Hikma Specialized brings with it a deep understanding of this fast changing therapeutic area and applies scientific rigor and resources to work. Our agile business model optimally organizes us to quickly meet the diverse needs of cancer patients, health care providers and systems in Egypt, and bring the next generation of cancer treatments to patients at affordable prices.'

As a fully integrated unit within Hikma's global network, the Specialized Business Unit will leverage expertise from its parent company to help accelerate local capabilities, ensure continued understanding of evolving patient needs, and drive the oncology business in Egypt and the region at large. In line with this strategy, in 2015, Hikma Pharmaceuticals acquired EIMC United Pharmaceuticals ('EUP'), a local Egyptian pharmaceutical manufacturing company specializing in oncology products. The acquisition strengthened Hikma's ability to bring high tech locally manufactured oral and injectable oncology products onto the Egyptian market. With the acquisition, Hikma has acquired an attractive portfolio and pipeline in the key strategic areas of oncology and injectables, with the potential to add around 50 products by 2020. The acquisition represented part of a strategic initiative by Hikma to ensure local manufacturing capability of high tech medicines in Egypt.

'Our commitment to providing high quality breakthrough medicines at affordable prices and our passion for improving the lives of patients is stronger than ever,' said Dr. Hassan Shafick Managing Director Hikma Egypt. 'In working towards our aspiration to cure cancer, our singular focus has been on ensuring a steady supply of high quality breakthrough medicines for cancer patients, particularly for those battling different forms of cancer. Now, with a more robust local manufacturing capability and with a global network and resources, provided by Hikma Pharmaceuticals internationally, we are optimally positioned to leverage all tools at our disposal to quickly acquire and locally produce compounds for cancer patients in Egypt and the MENA region at large.'

-- END --

About Hikma Pharmaceuticals Egypt

Hikma Pharmaceuticals Egypt manufactures and markets generic and in licensed pharmaceutical products with a focus on higher value, differentiated products spanning a broad range of therapeutic categories, including CNS, anti-infectives, cardiovascular and oncological therapeutic areas. Hikma entered the Egyptian pharmaceutical market through the acquisition of Alkan Pharma in 2007 this was followed ,in 2013, with the acquisition ofthe Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) allowing Hikma to strengthen the Group's position in the Egyptian market. End 2015 Hikma acquired EIMC United Pharmaceuticals ('EUP') a pharmaceutical manufacturing company specializing in oncology products. Today Hikma Pharmaceuticals Egypt occupies a leading position in the market and markets over 150 high quality branded generic products in the areas of CNS, anti-infectives, cardiovascular and oncology products.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics' based principally in the Middle East and North Africa ('MENA') region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million. For more information please view: www.hikma.com

For media inquiries please contact:
Wayak Communications
Ms. Amany Aboulfetouh
Mob: 01001557543
Email: amany.aboulfetouh@wayakcomm.com

Hikma Pharmaceuticals plc published this content on 07 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 June 2016 08:39:02 UTC.

Original documenthttp://www.hikma.com/en/media-center/news-and-press-releases/all-news/2016/07-06-2016.aspx

Public permalinkhttp://www.publicnow.com/view/E6EB0B0D49FF704DE14AFFB966799CAFE68D08DF